302 related articles for article (PubMed ID: 19023648)
1. IGF-1 receptor inhibitors in clinical trials--early lessons.
Weroha SJ; Haluska P
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):471-83. PubMed ID: 19023648
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
Iams WT; Lovly CM
Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
[TBL] [Abstract][Full Text] [Related]
5. Targeting insulin-like growth factor type 1 receptor in cancer therapy.
Atzori F; Traina TA; Ionta MT; Massidda B
Target Oncol; 2009 Dec; 4(4):255-66. PubMed ID: 19876700
[TBL] [Abstract][Full Text] [Related]
6. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
Sachdev D; Yee D
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
[TBL] [Abstract][Full Text] [Related]
8. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor pathway as a target for cancer therapy.
López-Calderero I; Sánchez Chávez E; García-Carbonero R
Clin Transl Oncol; 2010 May; 12(5):326-38. PubMed ID: 20466617
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
Paz K; Hadari YR
Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
[TBL] [Abstract][Full Text] [Related]
11. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.
Gualberto A; Pollak M
Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
[TBL] [Abstract][Full Text] [Related]
14. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
15. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
Gualberto A; Pollak M
Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
[TBL] [Abstract][Full Text] [Related]
17. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
18. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
[TBL] [Abstract][Full Text] [Related]
19. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy.
Werner H; Sarfstein R; Bruchim I
Expert Opin Investig Drugs; 2019 Dec; 28(12):1101-1112. PubMed ID: 31731883
[No Abstract] [Full Text] [Related]
20. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
